Jen‐Fue Maa

1.8k total citations
35 papers, 1.4k citations indexed

About

Jen‐Fue Maa is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Genetics. According to data from OpenAlex, Jen‐Fue Maa has authored 35 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Cardiology and Cardiovascular Medicine, 15 papers in Surgery and 10 papers in Genetics. Recurrent topics in Jen‐Fue Maa's work include Blood Pressure and Hypertension Studies (11 papers), Inflammatory Bowel Disease (10 papers) and Cardiovascular Syncope and Autonomic Disorders (8 papers). Jen‐Fue Maa is often cited by papers focused on Blood Pressure and Hypertension Studies (11 papers), Inflammatory Bowel Disease (10 papers) and Cardiovascular Syncope and Autonomic Disorders (8 papers). Jen‐Fue Maa collaborates with scholars based in United States, Germany and Canada. Jen‐Fue Maa's co-authors include Sally Hodder, Christopher M. Dezii, Hugh Kawabata, Judith S. Currier, Felicity Boyd, Anne Taylor, Oliver Flint, Rex A. Parker, Mustafa A. Noor and Daniel Seekins and has published in prestigious journals such as Circulation, Blood and Gastroenterology.

In The Last Decade

Jen‐Fue Maa

34 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jen‐Fue Maa United States	16	571	489	472	355	234	35	1.4k
Madéleine Durand Canada	21	383 0.7×	343 0.7×	258 0.5×	213 0.6×	313 1.3×	107	1.6k
Franck Boccara France	29	1.5k 2.6×	760 1.6×	968 2.1×	590 1.7×	522 2.2×	124	2.6k
Hugh Kawabata United States	15	415 0.7×	275 0.6×	269 0.6×	188 0.5×	132 0.6×	31	1.0k
Mpiko Ntsekhe South Africa	24	305 0.5×	329 0.7×	930 2.0×	79 0.2×	488 2.1×	97	1.7k
Andreas Ronit Denmark	16	252 0.4×	277 0.6×	85 0.2×	124 0.3×	101 0.4×	51	837
Alberto La Rosa Peru	14	737 1.3×	722 1.5×	54 0.1×	513 1.4×	109 0.5×	42	1.3k
Andrea Malagoli Italy	16	320 0.6×	158 0.3×	76 0.2×	47 0.1×	268 1.1×	53	1.0k
Ponnudurai Kuperan Singapore	17	47 0.1×	325 0.7×	102 0.2×	36 0.1×	86 0.4×	51	1.3k
Dietmar Zdunek Germany	22	37 0.1×	86 0.2×	706 1.5×	155 0.4×	205 0.9×	36	1.5k
Birgit Grund United States	18	875 1.5×	783 1.6×	76 0.2×	545 1.5×	74 0.3×	39	1.4k

Countries citing papers authored by Jen‐Fue Maa

Since Specialization

Citations

This map shows the geographic impact of Jen‐Fue Maa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jen‐Fue Maa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jen‐Fue Maa more than expected).

Fields of papers citing papers by Jen‐Fue Maa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jen‐Fue Maa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jen‐Fue Maa. The network helps show where Jen‐Fue Maa may publish in the future.

Co-authorship network of co-authors of Jen‐Fue Maa

This figure shows the co-authorship network connecting the top 25 collaborators of Jen‐Fue Maa. A scholar is included among the top collaborators of Jen‐Fue Maa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jen‐Fue Maa. Jen‐Fue Maa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Merli, Pietro, Annalisa Ruggeri, Mattia Algeri, et al.. (2019). Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Transfusion-Dependent β-Thalassemia Treated at the Bambino Gesù Children's Hospital, Rome, Italy. Blood. 134(Supplement_1). 969–969. 1 indexed citations

Aletaha, Daniel, Jen‐Fue Maa, Su Chen, et al.. (2019). Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 78(12). 1609–1615. 39 indexed citations

Hyams, Jeffrey S., Marla C. Dubinsky, Joel R. Rosh, et al.. (2018). The effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in paediatric patients with Crohn’s disease: a post hoc analysis. Alimentary Pharmacology & Therapeutics. 49(2). 155–164. 21 indexed citations

Louis, Édouard, Walter Reinisch, David A. Schwartz, et al.. (2018). Adalimumab Reduces Extraintestinal Manifestations in Patients with Crohn’s Disease: A Pooled Analysis of 11 Clinical Studies. Advances in Therapy. 35(4). 563–576. 17 indexed citations

Panaccione, Remo, William J. Sandborn, Geert D’Haens, et al.. (2018). Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn’s Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE Trials. Journal of Crohn s and Colitis. 12(8). 930–938. 15 indexed citations

Panaccione, Remo, Paul Rutgeerts, William J. Sandborn, et al.. (2017). Adalimumab Efficacy and Safety by Disease Duration: Analysis of Pooled Studies of Crohn's Disease. Gastroenterology. 152(5). S744–S744. 1 indexed citations

Parasrampuria, Dolly A., Jen‐Fue Maa, Victor Dishy, et al.. (2015). Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects. Clinical Drug Investigation. 36(2). 127–136. 5 indexed citations

Maa, Jen‐Fue, et al.. (2013). Efficacy of Amlodipine/Olmesartan Medoxomil ± Hydrochlorothiazide in Patients Aged ≥ 65 or < 65 Years With Uncontrolled Hypertension on Prior Monotherapy. Postgraduate Medicine. 125(2). 124–134. 7 indexed citations

Gurbel, Paul A., Kevin P. Bliden, Douglas Logan, et al.. (2013). The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Clopidogrel and Prasugrel. Journal of the American College of Cardiology. 62(6). 505–512. 107 indexed citations

10.

Gurbel, Paul A., Kevin P. Bliden, Douglas Logan, et al.. (2012). TCT-54 The Influence of Smoking Status On The Pharmacodynamics of Prasugrel and Clopidogrel:The PARADOX Study. Journal of the American College of Cardiology. 60(17). B17–B17. 3 indexed citations

11.

Neutel, Joel M., et al.. (2012). Efficacy of Olmesartan Medoxomil and Hydrochlorothiazide Fixed-Dose Combination Therapy in Patients Aged 65 Years and Older with Stage 1 and 2 Hypertension or Isolated Systolic Hypertension. American Journal of Cardiovascular Drugs. 12(5). 325–333. 5 indexed citations

12.

Neutel, Joel, et al.. (2012). Efficacy of Amlodipine/Olmesartan ± Hydrochlorothiazide in Patients Uncontrolled on Prior Calcium Channel Blocker or Angiotensin II Receptor Blocker Monotherapy. Advances in Therapy. 29(6). 508–523. 4 indexed citations

13.

Chin, Chee Tang, Tracy Y. Wang, Kevin J. Anstrom, et al.. (2011). Treatment with Adenosine Diphosphate Receptor Inhibitors—Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study design: Expanding the paradigm of longitudinal observational research. American Heart Journal. 162(5). 844–851. 47 indexed citations

14.

Punzi, Henry, et al.. (2011). Efficacy of Amlodipine and Olmesartan Medoxomil in Hypertensive Patients With Diabetes and Obesity. Journal of Clinical Hypertension. 13(6). 422–430. 9 indexed citations

15.

Neutel, Joel, et al.. (2011). Blood Pressure-Lowering Efficacy of an Olmesartan Medoxomil/Hydrochlorothiazide-Based Treatment Algorithm in Elderly Patients (Age ≥65 Years) Stratified by Age, Sex and Race. Drugs & Aging. 28(6). 477–490. 5 indexed citations

16.

DeJesus, Edwin, Benjamin Young, Javier O Morales-Ramirez, et al.. (2009). Simplification of Antiretroviral Therapy to a Single-Tablet Regimen Consisting of Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate Versus Unmodified Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes. 51(2). 163–174. 108 indexed citations

17.

Jayaweera, Dushyantha, et al.. (2008). Randomization to Once-Daily Stavudine Extended Release/Lamivudine/Efavirenz Versus a More Frequent Regimen Improves Adherence While Maintaining Viral Suppression. HIV Clinical Trials. 9(3). 164–176. 40 indexed citations

18.

Flandre, Philippe, Colombe Chappey, Anne‐Geneviève Marcelin, et al.. (2007). Phenotypic Susceptibility to Didanosine Is Associated with Antiviral Activity in Treatment‐Experienced Patients with HIV‐1 Infection. The Journal of Infectious Diseases. 195(3). 392–398. 10 indexed citations

19.

Noor, Mustafa A., Oliver Flint, Jen‐Fue Maa, & Rex A. Parker. (2006). Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS. 20(14). 1813–1821. 132 indexed citations

20.

Maa, Jen‐Fue, Dennis K. Pearl, & Robert Bartôszyński. (1996). Reducing multidimensional two-sample data to one-dimensional interpoint comparisons. The Annals of Statistics. 24(3). 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact